Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ANX1502 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ANX1502 SAD | EXPERIMENTAL | Participants will be administrated a single oral dose of ANX1502 at various ascending dose levels or matching placebo. |
| ANX1502 MAD | EXPERIMENTAL | Participants will be administrated multiple oral doses of ANX1502 at various ascending dose levels or matching placebo for 14 days. |
| Name | Type | Description |
|---|---|---|
| ANX1502 | DRUG | ANX1502 is a prodrug of ANX1439. |
| Placebo | DRUG | Placebo comparator. |
Key Inclusion Criteria: * Must be healthy as determined by medical evaluation including medical history, physical examination, vital signs assessments (including supine blood pressure, supine pulse rate, respiration rate, and temporal body temperature), 12-lead electrocardiogram (ECG), and laborato...
ANX1502 is an investigational small molecule being developed by Annexon, Inc. It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers, and its therapeutic area is classified as other, meaning it is not specifically tied to a single disease indication at this stage.
ANX1502 is being studied for use in healthy volunteers. It is an investigational small molecule in Phase 1 clinical development. The drug has not been approved for any medical condition, and its potential therapeutic applications are still being evaluated in early-stage clinical trials.
ANX1502 is developed by Annexon, Inc., a biopharmaceutical company traded on the stock exchange under the ticker ANNX. The company is conducting clinical research on this investigational small molecule, which is currently in Phase 1 development.
ANX1502 is in Phase 1 clinical development. It is an investigational small molecule, meaning it has not been approved by regulatory authorities. The drug is being studied in healthy volunteers to assess its safety and tolerability in early-stage trials.
ANX1502 has been studied in a Phase 1 clinical trial with the identifier NCT05521269. This trial, titled "Dose Study of ANX1502 in Healthy Volunteers," was conducted in the Netherlands and enrolled 135 participants. The study was randomized, double-blind, and controlled, and it has been completed.
ANX1502 is a distinct investigational small molecule developed by Annexon, Inc. There are no alternative names provided for this drug. It is currently in Phase 1 clinical development and has been studied in healthy volunteers in a completed clinical trial.